Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 14, 2026

Oct 14, 2026

•

3 min read

Biotech & Pharma Updates | October 14, 2026

🧬 Zealand Pharma, Generate:Biomedicines partner on AI-designed obesity, metabolic drugs, up to $1.2B deal, Verastem Oncology's (VS-7375) shows 50% objective response rate in Ph1/2 for KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma, Soufflé Therapeutics raises $135M Series A to advance three cell-targeted RNA programs into clinic

Christian Cuchapin, +1

Biotech & Pharma Updates | October 13, 2026

Oct 13, 2026

•

4 min read

Biotech & Pharma Updates | October 13, 2026

🧬 GSK pledges $800M to build biologics production facility and innovation hub in Pennsylvania, Asahi Kasei's Hovilpri (pritelivir) wins FDA approval for drug-resistant herpes simplex virus lesions in immunocompromised patients following Ph3 success, Roche, Rona Therapeutics license RNAi-based ALK7 obesity candidate for up to $1.16B

Christian Cuchapin, +1

Biotech & Pharma Updates | October 9, 2026

Oct 9, 2026

•

3 min read

Biotech & Pharma Updates | October 9, 2026

🧬 GSK joins Chai Discovery's AI drug discovery platform following successful wet-lab validation of protein designs, FDA approves Roche's Tecentriq (atezolizumab) for Stage III mismatch repair deficient colon cancer based on Ph3 data, TRex Bio prices $117M IPO to advance immune-regulating Treg-targeted drug pipeline

Christian Cuchapin, +1

Biotech & Pharma Updates | October 8, 2026

Oct 8, 2026

•

3 min read

Biotech & Pharma Updates | October 8, 2026

🧬 Novartis' Rhapsido (remibrutinib) wins FDA label expansion for symptomatic dermographism based on Ph3 data, Viatris to acquire Pacira BioSciences for $1.65B, expanding non-opioid pain management portfolio, Bristol Myers Squibb's Zenbexus (iberdomide) hits Ph3 progression-free survival endpoint in relapsed or refractory multiple myeloma

Christian Cuchapin, +1

Biotech & Pharma Updates | October 7, 2026

Oct 7, 2026

•

3 min read

Biotech & Pharma Updates | October 7, 2026

🧬 Cerevance's (solengepras) meets Ph3 primary endpoint, reducing off time in Parkinson's disease, paving path to FDA, Matchpoint Therapeutics raises $150M Series B to advance covalent medicines pipeline into clinic, GSK's Cabenuva (cabotegravir/rilpivirine) shows superior viral suppression in unsuppressed HIV patients in Ph3 trial

Christian Cuchapin, +1

Biotech & Pharma Updates | October 6, 2026

Oct 6, 2026

•

3 min read

Biotech & Pharma Updates | October 6, 2026

🧬 Shionogi to acquire IntraBio for $2B, gaining rare disease drug Aqneursa approved in two inherited disorders, AbbVie, Genmab's Epkinly (epcoritamab) cuts disease progression risk by 51% in Ph3 first-line diffuse large B cell lymphoma, Forbion raises €2.3B ($2.6B) across two funds to support ~30 high-potential biotechs

Christian Cuchapin, +1

Biotech & Pharma Updates | October 5, 2026

Oct 5, 2026

•

4 min read

Biotech & Pharma Updates | October 5, 2026

🧬 Bayer invests $2.2B in Ohio manufacturing site to expand U.S. pharma presence, Novartis acquires option on Abogen Biosciences' mRNA-encoded T cell engager, $575M upfront, $7.8B total, Vaxcyte's VAX-31 meets Ph3 endpoints against Pfizer's Prevnar 20 and Merck & Co.'s Capvaxive for pneumococcal disease

Christian Cuchapin, +1

Biotech & Pharma Updates | October 1, 2026

Oct 1, 2026

•

3 min read

Biotech & Pharma Updates | October 1, 2026

🧬 Sanofi pays Regeneron $1B upfront, up to $7B milestones for four early-stage immunology assets, Eli Lilly shares Ph3 cardiovascular outcomes data for Foundayo (orforglipron) in type 2 diabetes and obesity, Varda raises $251M Series D to manufacture pharmaceuticals in space

Christian Cuchapin, +1

Biotech & Pharma Updates | September 30, 2026

Sep 30, 2026

•

4 min read

Biotech & Pharma Updates | September 30, 2026

🧬 Roche, Zealand initiate Ph3 program for (petrelintide) in obesity after Ph2 amylin analog shows 9.8% peak weight loss, Eli Lilly shares Ph3 data on (retatrutide), GIP/GLP-1/glucagon triple agonist showing 25% body weight loss in obesity with type 2 diabetes, Pierre Fabre, Atara Biotherapeutics resubmit Ebvallo (tabelecleucel) BLA to FDA for Epstein-Barr virus-positive posttransplant lymphoproliferative disease following Ph3 trial

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 14, 2026

Biotech & Pharma Updates | October 13, 2026

Biotech & Pharma Updates | October 9, 2026

Biotech & Pharma Updates | October 8, 2026

Biotech & Pharma Updates | October 7, 2026

Biotech & Pharma Updates | October 6, 2026

Biotech & Pharma Updates | October 5, 2026

Biotech & Pharma Updates | October 1, 2026

Biotech & Pharma Updates | September 30, 2026

TLDR Biotech

FAQ

Media Partners